Q4 2025 Earnings Conference Call Announcement


  • SK Bioscience to hold face-to-face IR on Feb 5-6, 2026
  • Target: domestic institutional investors; Host: NH Investment & Securities
  • Purpose: Q4 2025 earnings and business update
  • IR materials to be posted on website on Feb 3
  • Schedule subject to change

KOSPI Filing Information


  • Filing: Corporate Briefing (IR) Holding (Notice Disclosure)
  • Company: SK Bioscience (302440)
  • Submission: SK Bioscience Co.,Ltd
  • Receipt: 02-03-2026
  • Under KRX KOSPI Market Division